Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49 551 308 0
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.70 billion
Profitability
Miscellaneous
Employees8,125
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable
Sartorius (ETR:SRT) Frequently Asked Questions
What is Sartorius' stock symbol?
Sartorius trades on the ETR under the ticker symbol "SRT."
When is Sartorius' next earnings date?
What price target have analysts set for SRT?
1 analysts have issued twelve-month target prices for Sartorius' shares. Their forecasts range from €141.00 to €141.00. On average, they expect Sartorius' share price to reach €141.00 in the next year. This suggests that the stock has a possible downside of 9.3%. View Analyst Price Targets for Sartorius.
What is the consensus analysts' recommendation for Sartorius?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sartorius.
Has Sartorius been receiving favorable news coverage?
Media headlines about SRT stock have been trending positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sartorius earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Sartorius.
Who are some of Sartorius' key competitors?
Some companies that are related to Sartorius include Carl Zeiss Meditec (AFX), Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Senseonics (SENS), Senseonics (SENS), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL) and Sernova (SVA).
What other stocks do shareholders of Sartorius own?
Who are Sartorius' key executives?
Sartorius' management team includes the folowing people:
- Dr. Joachim Kreuzburg, Chairman of Exec. Board & CEO (Age 54)
- Mr. Rainer Lehmann, CFO & Member of Exec. Board and Head of Fin., Information Technology & Bus. Process (Age 43)
- Ms. Petra Kirchhoff, Head of Corp. Communications & Investor Relations and Member of Supervisory Board (Age 50)
- Mr. Gerry Mackay, Head of Lab Products & Services Division & Member of Exec. Board (Age 56)
- Dr. René Fáber, Head of Bioprocess Solutions Division & Member of Exec. Board (Age 43)
What is Sartorius' stock price today?
One share of SRT stock can currently be purchased for approximately €155.50.
How big of a company is Sartorius?
What is Sartorius' official website?
How can I contact Sartorius?
The company can be reached via phone at 49 551 308 0.
MarketBeat Community Rating for Sartorius (ETR SRT)
MarketBeat's community ratings are surveys of what our community members think about Sartorius and other stocks. Vote "Outperform" if you believe SRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
